Stay updated with breaking news from Katrin Dubischar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Lancet's recent study reveals that a single-dose chikungunya vaccine is deemed safe and triggers a robust immune response in phase 3 trial, showing promising preventive potential.
The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% (263/266) of participants, according to a phase 3 randomized controlled trial published in The Lancet.
A single-dose vaccine for chikungunya was found safe and produced a strong immune response against the viral disease, according to the first phase 3 trial of the preventive published in The Lancet journal. However, the researchers were unable to investigate whether the VLA1553 vaccine
Chikungunya is a mosquito-borne disease caused by the chikungunya virus (CHIKV), which is endemic in some regions of Africa, Asia, and the Americas
After a single vaccination, VLA1553 induced antibody levels at a level that is considered to protect against disease among 99 per cent (263/266) of participants. There was no difference in immune response according to age, the researchers said.